Century Therapeutics (IPSC) Cash from Operations (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Cash from Operations data on file, last reported at 25262000.0 in Q1 2026.

• Cash from Operations for Q1 2026 came in at 25262000.0, up 27.04% year-over-year; the trailing twelve-month figure through Mar 2026 was 94515000.0 (up 17.46% YoY), and the FY2025 annual result was 103876000.0, up 5.68% from the prior year.
• Cash from Operations declined to 25262000.0 in Q1 2026 per IPSC's latest filing, from 16077000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 86753000.0 in Q1 2022 and troughed at 34623000.0 in Q1 2025.
• A 5-year average of 18445235.29 and a median of 25556000.0 in 2022 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations surged 491.15% in 2022, then sank 133.68% in 2023.
• A 5-year view of Cash from Operations shows it stood at 22907000.0 in 2022, then dropped by 14.51% to 26230000.0 in 2023, then advanced by 7.65% to 24223000.0 in 2024, then surged by 33.63% to 16077000.0 in 2025, then slumped by 57.13% to 25262000.0 in 2026.
• Business Quant data shows IPSC's Cash from Operations at 25262000.0 in Q1 2026, 16077000.0 in Q4 2025, and 25584000.0 in Q3 2025.